Nektar Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nektar Therapeutics sits in the top decile of US sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count).
Nektar Therapeutics: 37 sponsored US clinical trials, 1 recruiting.
Nektar Therapeutics sponsors 37 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 26 completed. 7 of these trials are in Phase 3-4 (later-stage) and 30 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.
Top-decile sponsor footprint
Nektar Therapeutics ranks in the top decile of sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
26 of 34 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
37 total, page 1 of 1
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
NCT06340360
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
NCT05664217
A Phase I Study of LY3471851 in Healthy Participants
NCT05565729
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
NCT04969861
A Single-Dose Study of LY3471851 in Healthy Participants
NCT04998487
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT04677179
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
NCT04646044
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
NCT04616196
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
NCT04433585
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
NCT04410445
A Study of LY3471851 in Participants With Eczema
NCT04081350
A Study of LY3471851 in Participants With Psoriasis
NCT04119557
A Study of LY3471851 in Healthy Participants
NCT04133116
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NCT04136756
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
NCT03785925
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
NCT03729245
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
NCT03802227
A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
NCT03556007
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
NCT03435640
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
NCT03138889
A Study of NKTR-358 (LY3471851) in Healthy Participants
NCT04380324
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
NCT02983045
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
NCT02915744
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
NCT02869295
Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
NCT02367820
Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain
NCT02362672
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
NCT01976143
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
NCT01991678
A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain
NCT01619839
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
NCT01492101
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
NCT01457118
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
NCT00856375
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
NCT00802945
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
NCT00806156
NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
NCT00598975
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 13 |
| Phase 3 | 7 |
What is open in the Nektar Therapeutics pipeline
1 recruiting of 37 indexed (3% open); 26 completed (70%).
Phase mix: 7 late (III/IV) vs 30 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nektar Therapeutics: open-pipeline peers nationwide
Peers matched on 37 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Nektar Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 37 trials (± recruiting share)
- Appalachian State University · 37 trials · 3% recruiting
- Bracco Diagnostics · 37 trials · 3% recruiting
- Carnegie Mellon University · 37 trials · 11% recruiting
- Cutera · 37 trials · 0% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Janssen Scientific Affairs · 3% recruiting · 37 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
- Eastern Cooperative Oncology Group · 3% recruiting · 141 trials
- Ethicon Endo-Surgery · 3% recruiting · 39 trials
Related
What to do with this Nektar Therapeutics page
37 registered trials is a research-attention snapshot, not an endorsement of Nektar Therapeutics or any single study.
- 1 of Nektar Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Nektar Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nektar Therapeutics pipeline card: 37 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.